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ABSTRACT
Influenza A viruses counteract the cellular innate immune response at several steps, including blocking RIG I-dependent activa-
tion of interferon (IFN) transcription, interferon (IFN)-dependent upregulation of IFN-stimulated genes (ISGs), and the activity
of various ISG products; the multifunctional NS1 protein is responsible for most of these activities. To determine the importance
of other viral genes in the interplay between the virus and the host IFN response, we characterized populations and selected mu-
tants of wild-type viruses selected by passage through non-IFN-responsive cells. We reasoned that, by allowing replication to
occur in the absence of the selection pressure exerted by IFN, the virus could mutate at positions that would normally be re-
stricted and could thus find new optimal sequence solutions. Deep sequencing of selected virus populations and individual virus
mutants indicated that nonsynonymous mutations occurred at many phylogenetically conserved positions in nearly all virus
genes. Most individual mutants selected for further characterization induced IFN and ISGs and were unable to counteract the
effects of exogenous IFN, yet only one contained a mutation in NS1. The relevance of these mutations for the virus phenotype
was verified by reverse genetics. Of note, several virus mutants expressing intact NS1 proteins exhibited alterations in theM1/M2
proteins and accumulated large amounts of deleted genomic RNAs but nonetheless replicated to high titers. This suggests that
the overproduction of IFN inducers by these viruses can override NS1-mediated IFNmodulation. Altogether, the results suggest
that influenza viruses replicating in IFN-competent cells have tuned their complete genomes to evade the cellular innate immune
system and that serial replication in non-IFN-responsive cells allows the virus to relax from these constraints and find a new ge-
nome consensus within its sequence space.
IMPORTANCE
In natural virus infections, the production of interferons leads to an antiviral state in cells that effectively limits virus replica-
tion. The interferon response places considerable selection pressure on viruses, and they have evolved a variety of ways to evade
it. Although the influenza virus NS1 protein is a powerful interferon antagonist, the contributions of other viral genes to inter-
feron evasion have not been well characterized. Here, we examined the effects of alleviating the selection pressure exerted by in-
terferon by serially passaging influenza viruses in cells unable to respond to interferon. Viruses that grew to high titers hadmu-
tations at many normally conserved positions in nearly all genes and were not restricted to the NS1 gene. Our results
demonstrate that influenza viruses have fine-tuned their entire genomes to evade the interferon response, and by removing in-
terferon-mediated constraints, viruses canmutate at genome positions normally restricted by the interferon response.
The influenza A viruses are members of the family Orthomyxo-viridae and cause annual epidemics and occasional pandemics
of respiratory disease with considerable public health and eco-
nomic impact (1, 2). The viral genome comprises eight single-
stranded RNA molecules of negative polarity, which are encapsi-
dated into distinct ribonucleoprotein particles (RNPs) containing
the viral polymerase andmultiple nucleoprotein (NP)monomers
(3–7). Upon recognition of sialic acid-containing cellular recep-
tors, the virus enters the cell by endocytosis and the viral genome
reaches the cytoplasm by hemagglutinin-mediatedmembrane fu-
sion at the late endosome (8). Transcription and replication of the
viral RNPs occur in the nucleus and aremediated by the polymer-
ase, a heterotrimer composed of the PB1, PB2, and PA subunits.
For transcription, the polymerase uses a cap-snatching mecha-
nism to generate viral mRNAs, whereas replication leads to the
production of progeny RNPs similar to those present in the virion
(3, 4, 6). Finally, progeny RNPs are exported from the nucleus by
a CRM1-dependent pathway and become incorporated in a spe-
cific manner into virus particles. These progeny virions bud from
lipid rafts at the plasma membrane in a process that requires the
specific action of the M1 and M2 proteins (9–13).
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As a consequence of influenza infection, the cell mounts an
innate immune response to restrict virusmultiplication. Themain
driver of this response is a group of cytokines collectively named
type I interferons (IFNs) (14). Expression of IFNs requires the
detection of virus-specific patterns (pathogen-associatedmolecu-
lar patterns [PAMPs]), which are recognized as nonself by cellular
sensors (pattern recognition receptors [PRRs]) (15), of which
RIG-I is relevant during the infection of epithelial cells by influ-
enza virus (16–18). RIG-I becomes activated by recognition of
double-stranded RNA (dsRNA) containing a 5=-triphosphate (19,
20) and signals downstream through an interaction with the mi-
tochondrial protein IPS-1/MAVS/VISA/Cardif. The consequence
of this downstream signaling is the activation of the transcription
factors IRF3, NF-B, and ATF-2/c-Jun, which activate IFN tran-
scription (reviewed in reference 21). Secreted IFNs act in an auto-
crine and paracrine fashion by activating the IFN receptor. The
signal is transmitted by the Jak/STAT pathway to the nucleus,
where it activates the transcription of hundreds of IFN-dependent
genes (ISGs), many of which have antiviral activity (PKR, Mx,
OAS, etc.) to help the cell to overcome virus infection and restrict
virus spread to neighboring uninfected cells (14, 22).
Viruses have evolved a variety of countermeasures to avoid
cellular innate immunity and maintain reasonable replication ef-
ficiency. Some viruses can block the activation of PAMP sensors or
inhibit downstream signaling, thereby diminishing IFN expres-
sion. Other viruses counteract IFN activity by targeting various
stages of signaling downstream from IFN receptor, and, finally,
many viruses directly inhibit the activity of one or several antiviral
ISG products (reviewed in reference 14). In addition, many lytic
viruses diminish the level of transcription and/or translation of all
cellular genes and hence indirectly downregulate the induction of
IFNs and ISGs. In the case of influenza A viruses, the nonstruc-
tural NS1 protein is the main IFN-counteracting factor. NS1 is a
small multifunctional protein involved in viral protein synthesis,
viral RNA replication, and virion production (23–27) that also
modulates cellular posttranscriptional RNAprocessing and trans-
port (28–31) (reviewed in reference 32). Influenza A viruses lack-
ing NS1 protein expression cannotmultiply in normal, IFN-com-
petent cells but are viable in cellular systems deficient in innate
immunity, although viral yields are still reduced compared to
those of wild-type virus (33, 34). This indicates that the primary
but not the only role of NS1 is to counteract the cellular IFN
response. This is achieved through a combination of several NS1-
host cell interactions, some of which are strain specific (35). These
include (i) inhibiting cellular transcription elongation and post-
transcriptional RNA processing (28, 36, 37), (ii) blocking RIG-I
activation (16–18, 38), (iii) interferingwith IFN signaling (39, 40),
and (iv) directly inhibiting specific ISG products, such as PKR and
RNase L (41–43).
In addition to NS1, other influenza virus genes have been re-
ported to alter the cellular IFN response; the viral polymerase
inhibits activation of IPS-1/MAVS, possibly as a consequence of
PB2 localization at the mitochondria (44, 45), while PB1-F2 pro-
tein appears to modulate the IFN response, although contradic-
tory results have been reported (46–49). In this report, we have
undertaken a nonbiased genetic approach to determine the viral
genes that normally play a role in modulating the cellular IFN
response. Our results show that themutations that appear in virus
populations upon serial passage in non-IFN-responsive cells not
only are detected in the main IFN response modulator NS1 but
also occur in essentially every viral gene. Moreover, most of the
virus mutants identified and subsequently characterized induce
more IFN than wild-type (wt) virus but do not contain alterations
in NS1. Interestingly, several of these mutants are particularly
prone to accumulating deletion-containing RNAs derived from
the genes encoding the polymerase subunits.
MATERIALS AND METHODS
Biologicalmaterials. In the course of this study, the following influenza A
strains were used: A/Victoria/3/75 (VIC), A/Puerto Rico/34 (PR8), and
NS1 (33). Encephalomyocarditis virus (EMCV) was used for the IFN
bioassay. The MDCK cell line was purchased from the ATCC. The A549
cell line (50)was obtained from J. A.Melero. The origin ofMDCK-V2 and
MDCK-V5 cell lines has been described (51), as well as the generation of
A549/pr(IFN-).GFP cells (52, 53). A549 cells stably expressing luciferase
under an interferon-stimulated response element (ISRE) promoter
[A549/pr(ISRE).Luc] were a kind gift fromG.Adolf, Boehringer Ingelheim,
Austria, and were engineered to express BVDV/NPro [A549/pr(ISRE).
Luc-BVDV-Npro] to render them IRF3 deficient and unable to generate
IFN (54).
Antibodies used in these procedures included monoclonal antibodies
against -actin (Sigma), phospho-Akt (Ser473; Cell Signaling Technol-
ogy), and polyclonal antibodies to ISG56 (Santa Cruz), MxA (Santa
Cruz), phospho-IRF3 (Ser396; Cell Signaling Technology), Akt (pan; Cell
Signaling Technology), cleaved caspase-3 (Asp175; Cell Signaling Tech-
nology), phospho-eIF2 (Ser51; Cell Signaling Technology), and STAT1
(Cell Signaling Technology). The specific anti-NS1 and anti-NP rabbit
antibodies (55, 56), anti-M1 mouse antibodies (12), and anti-NS1 rat
antibodies (24) were described previously.
Virological techniques. The influenza virus plaque assay was carried
out on MDCK-V2 cells as described previously (57). Viral plaques were
stained with crystal violet or by immunocytochemistry using sheep anti-
sera raised against purified and disrupted X31 (H3N2) virus (anti-X31;
Diagnostics Scotland) (58). For serial passage, a virus stock generated by
three consecutive steps of limiting dilution was used as initial inoculum.
Infections were carried out in sextuplicate at a multiplicity of infection of
103 PFU per cell on either MDCK or MDCK-V2 cultures (107 cells).
When complete cytopathic effect was observed, the supernatant was col-
lected, clarified, and used for a further infection cycle. The titers of each
serial passage virus ranged between 5 107 and 2 108 PFU per cell. For
virus purification, virus supernatants were clarified by centrifugation for
10min (10,000 g, 4°C) and sedimented through a 33% sucrose cushion
in TNE (50 mM Tris HCl–100 mMNaCl–10 mM EDTA, pH 7.5) for 1 h
(28,000  g, 4°C). The virus pellet was resuspended in TNE and sedi-
mented again on a 50-to-33% sucrose step gradient in TNE. The virus-
containing interface was collected, diluted in TNE, and sedimented under
the same conditions (24).
IFN activity in the culture supernatants was determined by a cyto-
pathic effect (CPE) reduction bioassay. Culture supernatants from cells
infected at 5 PFU/cell were harvested after 24 h postinfection (hpi) and
centrifuged at 1,500 g for 10 min to eliminate cellular debris. After UV
treatment to inactivate residual virus, the supernatantswas serially diluted
2-fold and added to A549/BVDV-Npro cell monolayers for 24 h prior to
infection with EMCV at 0.05 PFU/cell. Monolayers were fixed after 2 to 3
days and stained with crystal violet to monitor CPE. The number of wells
protected were converted to IFN bioassay arbitrary units using an IFN-
standard.
Mutant virus screening. For cell sorting, plates of A549/pr(IFN-
).GFP cells were infected at 0.04 FPU/cell. At 8 hpi, cells were
trypsinized, resuspended inMg2- andCa2-free phosphate-buffered sa-
line (PBS), passed through a 0.4-mm-pore-size filter to obtain single-cell
suspensions, and sorted in an Influx cell sorter (BD Bioscience). Fluores-
cence-activated cell sorting (FACS) analysis was performed on A549/
pr(IFN-).GFP cells following trypsinization to obtain single-cell suspen-
sions and fixation in PBS–1% formaldehyde. Expression of green
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fluorescent protein (GFP) was examined using a BD FACScan flow cy-
tometer, and data were analyzed using FlowJo (Treestar).
Specific mutations were engineered into recombinant virus genomic
pHH plasmids derived from the VIC strain using the QuikChange site-
directed mutagenesis kit from Stratagene as recommended by the manu-
facturer. The mutations were rescued into infectious virus by standard
techniques (24, 59).
Protein analyses. Western blotting and immunofluorescence were
carried out as described previously (60, 61). For immunofluorescence,
infected A549 cells were washed with PBS, fixed with 1% paraformalde-
hyde, and permeabilized with 0.5%Triton X-100 for 5min. The cells were
blocked with PBS–3% bovine serum albumin (BSA and incubated with
primary antibody diluted in PBS–1% BSA for 1 h at room temperature.
After washing with PBS, coverslips were further incubated with goat anti-
rabbit or goat anti-rat antibodies bound to Alexa 488 or Alexa 594 fluo-
rochromes. Coverslips were mounted with Prolong reagent and analyzed
by confocal microscopy using a Leica TSC SP5 microscope.
For the luciferase assay, A549/pr(ISRE).Luc or A549/pr(ISRE).Luc-
BVDV-Npro cells were infected at 5 FPU/cell and were treated 7 h later
with IFN- (Roferon A; Roche) at 104 units/ml or left untreated. At 13 h
postinfection, luciferase expression was determined using a luciferase as-
say system (Promega).
RNA analyses. The RNA present in purified virions was purified by
treatment with 0.5% SDS and 200 	g/ml proteinase K in TNE for 30 min
at 37°C followed by extraction with phenol-chloroform-isoamyl alcohol-
hydroxyquinoline and ethanol precipitation (62). Purified RNA was sep-
arated by electrophoresis on denaturing 4% polyacrylamide–6 M urea
gels and silver stained as described previously (62). Reverse transcription-
PCR (RT-PCR) for PB1, PB2, and PA segments was performed to deter-
mine the presence of deletion-containing RNAs. To detect the different
segments, the oligonucleotide 5=-GTCACGTCTCATATTAGTAGAAAC
AAGG-3= was used in combination with either 5=-AGCAAAAGCAGGT
CAATTATATTCAATATG-3= to detect PB2, 5=-CAAAAGCAGGCAAAC
CATTTGAA-3= to detect PB1, or 5=-GCAAAAGCAGGTACTGATTCGA
GA-3= to detect PA (virus-specific sequences are underlined). The reverse
transcription reaction was performed for 30 min at 42°C, and then PCR
was performed for 30 rounds of 94°C for 30 s, 55°C for 30 s, and 68°C for
2.5 min with a final extension time of 7 min at 68°C.
Deep sequencing. Deep sequencing of virus populations was per-
formed using the Illumina HiSeq2000 sequencer with the sequencing kit,
version 5. After removal of the four nucleotide bar codes used for multi-
plexing, more than 4 million single-end 76-nucleotide (nt) reads were
obtained for each sample. Deep sequencing of selected virus mutants was
performed with the Illumina HiSeq2000 sequencer using the HiSeq se-
quencing kit TruSeq v3. In these cases, more than 20 million paired-end
46-nt reads were obtained.
Sequence analysis. For alignment of short reads against the viral ge-
nome, the BWA algorithm (63) was employed, using the sequence of VIC
as a reference. In all cases BWA alignment parameters were established to
allow 5 mismatches and no gaps (n, 5; o, 0). SAMtools (64) were used for
the management of the files generated by BWA. The following strategy
was used for detecting genomic deletions. Every 46-nt read was split into
two 23-nt fragments. Each fragment was then independently aligned
against the VIC genome with BWA software, allowing up to 1 mismatch
and no gaps. The alignments of two fragments of a single 46-nt read in the
same strand of the same viral segment at a distance 38 ormore nucleotides
(indicating a gap of 15 or more nucleotides) were scored as positive and
retrieved. To obtain other junction-compatible read alignments that do
not lie in the exact middle of a 46-nt read, the entire process was repeated
with fragments of 20 to 26 nt, 21 to 25 nt, 22 to 24 nt, 24 to 22 nt, 25 to 21
nt, and 26 to 20 nt. For each sample, all junction-compatible alignment
events with a gap size of 15 nt or more and that occurred in at least 2
different reads were considered for subsequent analysis.
RESULTS
Most of the experimental evidence regarding how influenza virus
circumvents the IFN response derives from studies of the pheno-
type of NS1 deletion or point mutants and from protein-protein
interaction studies involving NS1. In contrast, here we performed
anunbiased genetic screen to identify the viral genes that influence
the outcome of IFN-mediated innate immune responses to influ-
enza virus infections. Instead of increasing the IFN selection pres-
sure (65), we carried out serial passage of A/Victoria/3/75 (VIC)
influenza virus in non-IFN-responsive cells to release the virus
from sequence constraints imposed by the IFN response. A dia-
gram showing the experimental strategy employed is presented in
Fig. 1. A wt influenza virus was passaged serially in either MDCK
or MDCK-V2 cells, which express the V protein of parainfluenza
virus type 2 (PIV2) and are thus insensitive to IFN-/, since V
targets STAT1 for degradation in order to block IFN signaling
(51). Cells were infected at a low multiplicity of infection (MOI)
(0.001 PFU/cell) to (i) select for efficiently replicating viruses and
(ii) prevent the accumulation of defective virus (66). Six indepen-
dent serial passages were carried out in parallel to increase the
diversity of potential mutants generated.
Phenotypic and genetic analyses of passaged virus popula-
tions. After 10 serial passages, the relative efficiency of replication
of the various passaged stocks was evaluated. MDCK and
MDCK-V2 cells were infected at a lowMOI (0.001 PFU/cell) with
the parental virus,NS1 virus, or the passage 10 virus seriesM1 to
M6 and V1 to V6. At various times after infection, the titer of
infectious virus was assayed on MDCK-V2 cells and the ratios of
the maximum titers obtained following replication in MDCK-V2
cells to those in MDCK cells were determined. The parental virus
used for serial passage produced similar yields in both cell lines,
while the NS1 virus replicated to approximately 50-fold-higher
titers in MDCK-V2 cells than in MDCK cells (Fig. 2A). Viruses
serially passaged in MDCK cells produced about 2-fold-higher
titers in MDCK-V2 cells than in MDCK cells, but strikingly, vi-
ruses that had been selected by passage through MDCK-V2 cells
FIG 1 Diagram of virus serial passage history. MDCK-V2 or MDCK cell cul-
tures were serially infected at a multiplicity of infection around 0.001 PFU/cell
with A/Victoria/3/75 virus. The initial infecting virus was generated by three
steps of endpoint dilution to limit the presence of defective virus particles. Six
replicates were carried out in each cell line, generating passage series V1 to V6
(in MDCK-V2 cells) and M1 to M6 (in MDCK cells).
Pérez-Cidoncha et al.
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replicated significantly better inMDCK-V2 cells thanMDCK cells
(approximately 10-fold) (Fig. 2B and C), strongly suggesting that
some of the viruses within this population do indeed replicate
better than wt virus in non-IFN-responsive cells but are presum-
ably selected against in IFN-competent cells. To confirm this,
some of the passage 10 virus populations of the V and M series
were used to infect either MDCK or MDCK-V5 cells, a different
cell line that expresses the V protein of parainfluenza virus type 5
(PIV5), which also blocks IFN signaling (51). Similar results were
obtained; specifically, the viruses passaged in MDCK-V2 cells
yielded higher titers in MDCK-V5 cells than in parental MDCK
cells, whereas viruses passaged in MDCK cells did not (Fig. 2D).
The phenotype of the passaged virus populationsmight be due
to the presence of many mutations affecting several genes or to a
small number of mutations concentrated in one viral gene, for
example, NS1. If the latter scenario was the case, then it would be
expected that deep sequencing of the viral populations would re-
veal a greater level of variation in one particular viral gene than the
others. To determine whether this was the case, we carried out
deep sequencing of purified RNA from passage 10 virions of the V
or M series. Under the conditions used, an average of 2,342 reads
per position were obtained, and no overall change in the consen-
sus sequence was observed. Moreover, no specific position could
be identified that showed significant sequence variation in the
V1-V6 passage series compared to the viruses passaged in MDCK
cells (data not shown). These results suggested thatmany different
mutations across the virus genome may account for the pheno-
type observed.
Screening and characterization of relevant virus popula-
tions. In view of these sequencing results, we next attempted to
isolate individual mutant viruses from within the population of
viruses selected by passage throughMDCK/V2 cells that activated
the IFN induction cascade upon infection. In A549 cells engi-
neered to express GFP under the control of the IFN promoter
[A549/pr(IFN-).GFP cells] (52), GFP expression acts as amarker
for activation of the IFN induction pathway. These cells were in-
fected with each of the passage 10 V1-V6 virus populations or the
M1MDCK-passaged virus and sorted for GFP expression (theM1
MDCK-passaged virus could contain spontaneous mutants af-
fected in IFN counteraction but was included to set a background
value). This sorting strategy would reveal mutant viruses able to
induce high levels of IFNbutmight not identifymutants unable to
FIG 2 Replication efficiency of serially passaged viruses in MDCK and non-IFN-responsive MDCK cells. (A) Replication kinetics of wt and NS1 viruses in
MDCK-V2 (gray lines) andMDCK cells (black lines). Cell cultures were infected with the initial virus stock (solid lines) or NS1 virus (dotted lines) at anMOI
of 0.001. At the indicated times after infection, samples were obtained from the culture supernatant, and the viral titers were determined by plaque assay in
MDCK-V2 cells. (B) The efficiency of replication of the various viruses of theM and V passage series were evaluated by low-multiplicity infections inMDCK-V2
and MDCK cells after 10 serial passages. Cultures were infected with either the initial virus stock (P0), one of the M1 to M6 or V1 to V6 viruses, or NS1 virus
at a multiplicity of 0.001 PFU/cell. At various times after infection, samples were collected and titers were determined on MDCK-V2 cells. Data are ratios of
maximal titers of infections in MDCK-V2 to those in MDCK cells, as shown in panel A (averages and standard deviations for 3 replicates). *, P 
 0.05. (C)
Absolute titers of a representative kinetics experiment. (D) The efficiency of replication of some viruses of the M and V passage series was evaluated by using
low-multiplicity infections in eitherMDCK-V5 andMDCK cells after 10 serial passages. Cultures were infected with either the initial virus stock (P0) or theM1,
M6, V1, V6, orNS1 virus at a multiplicity of 0.001 PFU/cell. At various times after infection, samples were collected and titers were determined onMDCK-V2
cells. Data are ratios ofmaximal titers of infections inMDCK-V2 to those inMDCK cells, as shown in panel A (averages and standard deviations for 3 replicates).
*, P
 0.05.
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counteract IFN signaling. The infections were carried out at low
multiplicity (0.04 PFU/cell) to reduce the possibility of dual infec-
tion of a single cell. Two sorting strategies were used: 1,000 to
9,000 bulk positive cells from each passaged population were col-
lected and plated onto cultures of MDCK-V2 cells to rescue the
selected population of progeny viruses, or alternatively, single
positive cells were plated onto MDCK-V2 cells to rescue individ-
ual mutant viruses (see below).
The genotypes of the bulk virus populations passaged in
MDCK-V2 cells and selected by cell sorting (populations VS1 to
VS6) were analyzed by deep sequencing of virion RNA on the
Illumina platform, using viruses from one of the populations pas-
saged inMDCK cells and sorted in parallel after infection of A549/
pr(IFN-).GFP cells as a control (population MS). The average
sequence variability per genome position in all populations was
0.35%. Therefore, we chose 5% (a 10-fold increase in variabil-
ity) as the limit to identify potential nucleotide changes in the
selected population of viruses that may influence the ability of
influenza A virus to circumvent the IFN response. A number of
positions in the genome of these selected populations (popula-
tions VS1 to VS6) showed a significant increase in sequence vari-
ation using this criterion and were not particularly variable in the
control selected MS population that was passaged in MDCK cells
(Table 1). The 41 positions that were specifically variable in pop-
ulations VS1 to VS6 mapped to all viral RNA segments except NP
and identified a potential landscape of mutations associated with
an enhanced ability to activate the IFN response or a diminished
ability to inhibit it. Among sequence positions that were specifi-
cally variable in populations V1 to V6, 11 showed high variability
in more than one passage series (Table 1). This suggests that they
mutated independently during passaging and hence may repre-
sent positions relevant for the regulation of IFN induction. In
addition, 24 of the variable positions showed changes that would
lead to 25 amino acid substitutions in viral proteins (Table 1).
When the nucleotide changes detected in these 41 variable posi-
tions were compared to the influenza virus sequence databases,
many of the synonymous changes corresponded to positions
that are not phylogenetically conserved (13 out of 17) (Table 1);
TABLE 1 Mutations detected in passaged virus populationsa
a The frequency of specific mutations detected in virus populations passaged in MDCK-V2 cells and sorted for
GFP expression (populations VS1 to VS6) is presented, using 5% as the lower threshold. For comparison, the
frequency of these mutations in a control population passaged in MDCK cells and sorted for GFP expression
(MS) is also presented. The conservation of these positions in the influenza sequence database is denoted as
conserved (C; blue), low variable (LOW V; light blue; 10
 n
 100), or variable (V; n 100), and the number
of instances each mutation appears among the total number of sequences screened is indicated. The mutations
leading to amino acid change are highlighted in green, and the amino acid change is indicated.
Pérez-Cidoncha et al.
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however, most of the amino acid substitutions were observed at
positions that are hightly phylogenetically conserved (18 out of
25) (Table 1). These observations suggest that the many synony-
mous changes imply random drift, whereas the nonsynonymous
changes were positively selected for during passage through
MDCK-V2 cells, with some of thesemutations resulting in viruses
that more readily activate the IFN induction cascade, since they
also induced expression of GFP in the A549/pr(IFN-).GFP cells.
As this analysis was done at the population level, it is not possible
to know whether some of the synonymous changes were cose-
lected with those involving amino acid alterations.
Identification andphenotypic characterization of individual
virus mutants. To isolate individual virus mutants potentially af-
fected in their activation of the IFN response, single cells scored as
positive for GFP expression after infection of A549/pr(IFN-
).GFP cells with the passage 10 V1 to V6 viruses at a low MOI
(0.04 PFU/cell) were plated individually onto microcultures of
MDCK-V2 cells, and the supernatants of cells showing a cyto-
pathic effect were collected. Out of around 1,200 wells containing
individual GFP-positive cells, viruses were recovered from 109
wells after endpoint dilution. There are a variety of possible rea-
sonswhynot all GFP-expressing cells yield infectious progeny. For
example, it has been shown that every virus population contains
manymutants that are not viable but can express virus proteins or
even replicate intracellularly (67); alternatively, some infected
cells may be coinfected with defective particles that interfere with
the replication of wt viruses. Around 75% of these viable viruses
showed GFP expression higher than that of wt virus when tested
by reinfection of A549/pr(IFN-).GFP cells, and 6 of these were
chosen for further analysis after preliminary phenotype character-
ization. First, the relative virus yield in IFN-responsive versus
non-IFN-responsive cells was measured (Fig. 3). All selected mu-
tants replicated efficiently in multicycle experiments in non-IFN-
responsive cells. In comparison, in IFN-responsive cells, mutant 2
grew to much lower titers (Fig. 3A), while mutants 18, 20, and 21
yielded smaller reductions or slower kinetics (Fig. 3B).Mutants 14
and 17 gave similar final virus yields in both cell types, although
mutant 14 showed protracted kinetics in IFN-competent cells
(data not shown). Comparison of virus plaque size in MDCK
versus MDCK-V2 cells revealed that only mutant 2 showed a re-
duction in plaque size in IFN-responsive cells, which was compa-
rable to that of NS1 virus (Fig. 3C). Furthermore, analyses of
virus protein expression and localization during high-multiplicity
infections in A549 cells showed only minor differences from wt
virus (data not shown).
Next we analyzed the interplay of these mutants with the in-
fected cell. The expression ofGFP after high-multiplicity infection
of A549/pr(IFN-).GFP cells with the 6 selected mutant viruses is
shown in Fig. 4A. Consistent with these results, all mutant viruses
triggered the expression of antiviral factors to levels 10- to 50-fold
FIG 3 Replication efficiency of wt and individual mutant viruses in MDCK
and MDCK-V2 cells. (A) The efficiency of replication of wt and various mu-
tant viruses was evaluated by determination of maximal titers after low-mul-
tiplicity infections in eitherMDCK-V2 andMDCK cells, as indicated in Fig. 2.
Values are averages and standard deviations from 3 experiments. *, P
 0.05;
**, P 
 0.01. (B) Kinetics of virus multiplication at low MOI. The titers at
various times postinfection of MDCK-V2 (black lines) or MDCK (gray lines)
cells were determined by plaque assay in MDCK-V2 cells. (C) Plaque size
analysis of wt or mutant viruses. Wt or mutant viruses (mutant 2 or NS1)
were used for plaque assay in parallel in MDCK-V2 or MDCK cell cultures.
After staining, the plaque size was determined using Image J software. The
numbers of plaques measured were 176 (wt), 229 (NS1), and 116 (mutant 2)
in each cell line. **, P
 0.01; ***, P
 0.001; ****, P
 0.0001.
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higher than wt virus after high-multiplicity infection of human
epithelial A549 cells, although this was lower than the induction
observed following a parallel infection with NS1 virus (Fig. 4B).
Likewise, all mutant viruses were able to induce the expression of
IFN-inducible genes, as demonstrated by the accumulation of lu-
ciferase reporter upon high-multiplicity infection of A549 ISRE-
luc cells, in contrast to wt virus infection, which does not activate
luciferase expression (Fig. 5A). In addition, some of the mutant
viruses (mutants 2, 14, and 21) had a reduced ability, compared to
wt virus, to block the upregulation of luciferase by exogenously
added IFN (Fig. 5B).
To further analyze the interplay of these mutant viruses with
the host cell, the expression of ISGs and the induction of specific
signaling pathways were determined by Western blotting follow-
ing high-multiplicity infection, using wt and NS1 viruses as ref-
erences (Fig. 6). These studies revealed the grouping of themutant
viruses into three phenotypes. Infection with mutant 2 led to a
response somewhat similar to that observed in NS1 virus infec-
tion: strong activation of IRF3, phosphorylation of eIF2 (a
marker of PKR activity), and partial induction of apoptosis. In
addition, mutant 2 infection showed induction of MxA, which
was not observed for NS1 virus infection (Fig. 6), probably as a
consequence of NS1 inducing apoptosis, leading to subsequent
degradation of STAT1 by caspases (68). Mutants 20 and 21 be-
haved similarly; their infection led to partial activation of IRF3,
expression of ISGs (MxA and ISG56), and activation of Akt (a
consequence of NS1-dependent activation of PI3K [69]) (Fig. 6),
but neither of these mutants induced apoptosis significantly. Of
note, no strict correlation was observed between the levels of ex-
FIG 4 Induction of interferon by wt or mutant influenza viruses. (A) Virus
progeny from individual A549/pr(IFN-).GFP cells that were sorted as GFP
positive and infected at low multiplicity was recovered after limiting-dilution
infections in MDCK-V2 cells. The ability of these viruses to induce GFP ex-
pression after infection of A549/pr(IFN-).GFP cells was quantified by FACS,
using wt and NS1 viruses as references. The results are representative of 3
independent experiments, in which 10,000 events were measured for each
sample. (B) The ability of mutant viruses to induce the secretion of antiviral
factors was tested by infecting of A549 cells at 5 PFU/cell, using wt and NS1
viruses as references. Culture supernatants were collected at 24 hpi, and their
ability to interfere with EMCV infection of A549/BVDV-Npro cells was deter-
mined by endpoint dilution, as described inMaterials andMethods. ****, P

0.0001.
FIG 5 Activation of the ISRE by wt and mutant viruses. Cultures of A549/
pr(ISRE).Luc (A) or A549/pr(ISRE).Luc-Npro (B) cells were infected at an
MOI of 5 PFU/cell or mock infected with the indicated mutants or wt virus as
a reference. A549 NPro/ISRE-luc cells constitutively express the BVDV NPro
protein, which degrades IRF3; as a result, these cells cannot produce endoge-
nous IFN (54). At 7 hpi, IFNwas added to the indicated samples, and at 13 hpi,
total cell extracts were prepared and luciferase activity was determined as de-
scribed in Materials and Methods. Virus infection was verified by determina-
tion of NP accumulation by Western blotting, using -actin as a loading con-
trol (C). *, P
 0.05; **, P
 0.01; ***, P
 0.001.
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pression of ISGs and the corresponding levels of IFN activity se-
creted (Fig. 4B). These differences may be a consequence of the
different kinetics of activation of these proteins. Finally, mutants
14, 17, and 18 did not show a clear phenotype in these assays, other
than robust activation of Akt by infection with mutant 14.
Genotype of individual virus mutants with an altered re-
sponse to interferon.To identify the genetic alterations present in
the mutants described above that could be responsible for their
observed phenotypes, their full genome sequence was determined
by deep sequencing of virion RNA. The results are presented in
Table 2. Nucleotide changes observed in the consensus sequence
of the mutants compared with the initial virus used to start serial
passages are in red. In addition, nucleotide changes that, although
not altering the consensus sequence, reflect a significant propor-
tion of the virus sequences at the corresponding position (i.e.,
higher than 30%) are in blue. The proportion of the alternative
nucleotide in all positions recorded (percent alternative nucleo-
tides) and the genomic heterogeneity found in the original virus
stock (percent variation in the initial, nonpassaged virus [Mi])
and in the virus isolated after sorting of cells infected with the
control virus populations (percent variation in MS) are also pre-
sented as a reference. Some of the recorded positions were very
variable in the control virus populations and are highlighted in
yellow, as for example mutant 2, position HA 700. We infer that
these positions in the virus sequence can easily drift and therefore
consider them probably irrelevant for the phenotype of the corre-
sponding mutant. Other positions have very low variability in the
control virus populations (see for instance mutant 2, position NS
217); these are highlighted in orange and were considered poten-
tially relevant for the virus phenotype. A number of these nucleo-
tide changes led to mutations at the protein level, and the amino
acid changes are indicated (Table 2). Some corresponded to posi-
tions that had low variation in the control viruses and that were
phylogenetically conserved in the influenza A database (high-
lighted in blue) or showed lowphylogenetic variation (highlighted
in light blue). Sequence analysis of virus populations passaged in
non-IFN-responsive cells and selected by cell sorting showed that
most of the amino acid changes detected did not map to the NS1
protein. In fact, the only NS1 mutation observed was I64T (NS
217) in the NS1 of mutant 2; none of the other mutant viruses
encoded altered NS1 proteins. The phenotype of mutant 2 was
similar to that ofNS1 virus, for which it is tempting to speculate
that mutation NS1 I64T is responsible. The relevance of the mu-
tations identified in mutants 14 to 21 is not clear at this point,
although it is noteworthy thatmutants 17 to 21 contain alterations
in either M1 (mutant 18, I115M, and mutants 17, 20, and 21,
D30N) or M2 (mutants 17, 20, and 21, A86S). The mutations
M1-I115M and M2-A86S have been detected very seldom (either
0/6,607 or 1/6,456-fold) (Table 2) and could be relevant for the
mutant phenotype. Mutant 14 has a mutation in the polymerase
domain of PB1 (N455D) (Table 2) that could alter its RNA repli-
cation efficiency and be the reason for its protracted replication
kinetics.
To verify whether the mutations identified in this screen were
relevant for the observed phenotype, some of them were intro-
duced into infectious virus by reverse genetics using the VIC virus
genetic background. Specifically, rescue of mutations NS1-I164T,
M2-A86S, M1-I115M, and M1-D30N was attempted. All rescued
viruses were viable except mutant M1-D30N, which could be res-
cued only in combination with mutation M2-A86S (i.e., as found
in mutants 17, 20, and 21, described above). To analyze the phe-
notypes of these recombinant viruses, the abilities of rescued vi-
ruses to activate expression of an ISRE-responsive luciferase re-
porter and to induce IFN secretion from infected cells were
examined (Fig. 7). Recombinant mutants NS1-I64T, M1-I115M,
and M1-D30N/M2-A86S showed luciferase inductions similar to
those observed in the original mutants 2, 20, and 21, respectively,
while mutation M2-A86S alone did not show a clear phenotype.
Similar results were obtained for IFN induction (Fig. 7B).
Some IFN-inducing virus mutants are particularly prone to
generating defective interfering particles. Since the induction of
IFN has been associated with the presence of defective interfering
(DI) viruses in both influenza viruses and paramyxoviruses (70–
73), we used bioinformatic analysis of the deep-sequencing data
for each mutant virus to detect and quantitate the presence of
internal deletion DI RNAs in the purified virions. An example of
the results is presented in Fig. 8, the summary of deletion-contain-
ing RNA accumulations is shown in Tables 3 and 4 and the com-
plete data set is available via the supplemental material. A large
number of deletions were observed that were individually very
infrequent and widely distributed across all genes of the various
viruses (although they are clearly more abundant in the polymer-
ase genes) (Table 3). These deletions could be interpreted as the
result of commonpolymerase errors during replication.However,
they would not be efficiently amplified and/or encapsidated, and
therefore each one was identified only a few times in the data set.
More abundant deletions were identified that were preferentially
derived from a subset of viral genes and were differentially repre-
sented in the wt and mutant viruses (Table 4). Among the abun-
dant deletions, two size classes could be distinguished: short (100
to 200 nt) (Table 4; also, see Fig. 8 as an example) or long (almost
2,000 nt) (Table 4; also, see Fig. 8 as an example). The abundant
FIG 6 Activation of the interferon response by wt or mutant influenza virus
infection. The induction of ISGs (MxA and ISG56) and activation of cell sig-
naling pathways (p-IRF3, p-Akt, c-Casp3, STAT1, and p-eIF2a) were analyzed
by Western blotting with specific antibodies at 16 hpi with the indicated mu-
tant viruses, using uninfected cells (UI) and cells infected with wt or NS1
viruses as references. Virus infection was detected by Western blotting with
antibodies specific for NS1 and NP, using -actin as a loading control.
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RNAs containing short deletions were detected exclusively from
the PB2 segment of mutants 18 and 20 and were not detectable in
other segments or mutants (Table 4); the origin of these differ-
ences is unclear at present. The abundant RNAs containing long
deletions were exclusively derived from the polymerase genes
(Table 4 and Fig. 8; also, see the supplemental material) and could
represent classical DI RNAs (74). The accumulation of long-dele-
tion RNAswasmany-fold higher inmutants 18, 20, and 21 than in
the other mutants or the wt virus, as determined by analysis of the
deep-sequencing data (Table 4; also, see the supplemental mate-
rial), with mutant 17 representing an intermediate situation. The
accumulation of deletion-containing RNAs by specific mutants
was verified by PCR amplification using terminal oligonucleotide
primers specific for the polymerase genes (Fig. 9). Although prep-
arations of all mutants were prepared in parallel at low MOI, it
could be argued that these disparities arose from different passage
histories of the various mutants. To rule out such a possibility,
mutants 18, 19, and 20 were plated onMDCK-V2 cells, individual
plaques were picked, and the viruses were tested for the presence
of deletion-containing RNAs as described above. The results indi-
cated that these mutants generated deletion-containing RNAs
very frequently (Fig. 9, lanes 18.3, 20.1, and 21.7). Interestingly,
the sizes of the DI RNAs observed after plaque purification were
different from those that accumulated in the corresponding (non-
plaque-purified) mutant virus stock, indicating that they arose as
new deletions in the single plaques andwere not carried over from
the original virus.
DISCUSSION
Complex interaction between influenza virus and the cellular
innate immune response. Like many other viruses, influenza A
viruses need to counteract the cellular innate immune response in
order to achieve a productive infection. Most of this viral coun-
teraction is mediated by the NS1 protein (21, 32, 33, 75), although
PB2 has also been implicated (44, 45). The approach taken here
naïvely questioned the genetic solutions that the virus could adopt
within its sequence space to optimize its replication under non-
IFN-responsive conditions and hence could identify other con-
TABLE 2 Mutations detected in individual virus mutantsa
a The mutations detected in individual virus mutants are presented. Mutations that appear as such in the
consensus sequence are in red. Those that do not appear as mutations in the consensus sequence but are
present in a proportion over 30% of the virus sample are indicated in blue. Amino acid changes in yellow are
very variable in the control virus populations, and those in orange have very low variability in the control virus
populations. For comparison, the frequencies of these mutations in the initial, nonpassaged virus (Mi) and in a
control population passaged in MDCK cells and sorted for GFP expression (MS) are also presented. The
conservation of these positions in the influenza virus sequence database is denoted as conserved (C; blue), low
variable (LOW V; light blue; 10
 n
 100), or variable (V; n 100), and the number of instances each
mutation appears among the total number of sequences screened is indicated.
Pérez-Cidoncha et al.
4640 jvi.asm.org Journal of Virology
 o
n
 June 11, 2014 by ST ANDREW
S UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
straints imposed by the innate immune system. The mutations
identified in several virus populations that replicate to higher
titers in non-IFN-responsive cells than in IFN-competent cells
presumably include genetic solutions which are normally re-
stricted in an IFN-responsive systembutwhich viruses are allowed
to adopt when the innate immune response is ablated. The exper-
imental approach used does not necessarily guarantee that iden-
tified mutations in the selected virus populations affect positions
normally involved in restricting the IFN response. However, two
observations suggest that this is likely: (i) the repetitive identifica-
tion of a fraction of these mutations in several virus populations
that evolved independently and (ii) the observation that most of
the amino acid changes detected affect very phylogenetically con-
served positions. In addition, a number of mutations were iden-
tified in individual IFN hyperinducer virus clones selected in par-
allel. The complete set of mutations is summarized in Fig. 10. It is
clear that amino acid changes were not restricted to the NS1 pro-
tein. Rather, theHA,M1, and polymerase genes showed a number
of mutations comparable to that observed in NS1, while NP and
NA were the least mutated genes. Among the amino acid changes
detected in the polymerase, PB2-G693E stands out as potentially
altering the nuclear localization signal (NLS) and hence importin-
alpha binding (76), while PA-L589I is located at the PB1 binding
site (77, 78). Two amino acid changes were observed at positions
phylogenetically conserved within the NS1 protein effector do-
main; E172K and N176I localize to the cleavage and polyadenyla-
tion specificity factor (CPSF)-binding region (35, 79–82). Finally,
M1-T139I affects a conserved position in the protein sequence
that is located at the dimer interaction surface in the M1 crystal
structure (83, 84). However, this genomic analysis cannot discern
whether these mutations affect directly virus counteraction of
IFN, since they could also reflect random passenger or compen-
satory mutations that might be linked to the relevant ones. Alto-
gether, the landscape of mutations suggests that the virus has
foundmultiple solutions in its adaptation to efficiently replicate in
a non-IFN-responsive system, and among themutants selected by
IFN-dependent GFP expression, only a fraction had mutations
that affect the well-known NS1 modulator of the innate immune
response. These results are in contrast with a recently published
mutagenesis study of the influenza genome (85) in which only the
hemagglutinin head and NS1 protein showed sufficient structural
flexibility to allow small insertions without altering virus viability.
Altogether, the results presented here indicate that under normal
replication conditions, the virus sequence space is restricted in
essentially every gene by the cellular innate immune response and
ablating the IFN response allows the virus to explore new possi-
FIG 7 Phenotype of recombinant virus mutants. The capacity of mutant vi-
ruses to induce luciferase under the control of an ISG promoter (A) was tested
by high-multiplicity infection of A549/pr(ISRE).Luc, using wt virus as refer-
ence. The capacity ofmutant viruses to induce the secretion of antiviral factors
(B) was tested in infections of A549 cells at 5 PFU/cell, using wt and NS1
viruses as references. Culture supernatants were collected at 24 hpi and their
ability to interfere with EMCV infection of A549/BVDV-Npro cells was deter-
mined by endpoint dilution and is presented in arbitrary units. *, P 
 0.05;
***, P
 0.001.
FIG 8 Deletion-containing virus RNAs detected by deep sequencing. The
figure shows an example of the results obtained by bioinformatics analysis of
the deep-sequencing data of wt and mutant virion RNAs (PB1 RNA segment;
comparison of mutant 20 and wt virus). The bars indicate the sequence dele-
tions mapped in the RNA segment coordinates. The gray scale indicates the
frequency of each particular deletion in the deep-sequencing data. Only dele-
tions larger than 15 nt and presentmore than 5 times are shown. The complete
deletion data set for all viruses is available via the supplemental material.
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bilities compatible with good replication fitness, some of which
affect levels of IFN induction.
Poor IFN blockers or IFN hyperinducers? The phenotypic
and genotypic analyses of the individual virus clones selected
showed two distinct groups, one represented by clone 2 and the
other including clones 18, 20, and 21 and to a lesser extent clone
17. Clone 2 virus is phenotypically similar to NS1 virus, as it
cannot restrict IFN induction or IFN-induced ISG expression and
contains an I64T mutation in NS1. This suggested that this single
change is sufficient to abolish the virus capacity to counteract the
IFN-mediated response to infection, a contention that was veri-
fied by the phenotype of the recombinant virus containing NS1-
I64T as a single mutation (Fig. 7). In contrast, the clone 18/20/21
group of viruses did not show mutations in NS1 protein, and
hence their capacity to counteract the IFN response should be
normal. However, these mutants still induced higher levels of IFN
than wt virus. This apparent contradiction could be explained by
the fast generation of deleted genomic RNAs in the 18/20/21
group compared to wt or clone 2 viruses. Whereas all viral clones
tested generated a low abundance of deletions essentially affecting
many viral RNAs, the 18/20/21 group of viruses accumulated large
numbers of deletion-containing RNAs originating only from the
polymerase segments, in line with the early studies characterizing
influenzaDIRNAs (74, 86).However, the clone 18/20/21 group of
TABLE 3 Total accumulation of deletion-containing RNAs in wt and mutant viruses
Virus
No. of total deletion-containing RNAs in segmenta
PB2 PB1 PA HA NP NA M NS
L S L S L S L S L S L S L S L S
Wt 2 5 2 2 27 8 4* 4 24* 6
2 7 6 29 3 35 5 5* 35*
14 4 24 44 20 150 6 2 6 5*
17 7 12 549 6 115 6 2 7 9 2 6*
18 756 37 120 254 831 16 2 2 4 21 2*7 4
20 2,136 98 848 2,698 3,434 72 18 24 20 10 20 30 *6 8 34 14*4 18
21 676 15 564 18 1,101 18 2 2* 5*
a The number of individual deletion-containing RNAs showing deletions longer than 15 nt that appear at least twice in each sample is given. Data were standardized according to
the number of deep-sequencing reads obtained for each virus sample and are presented as numbers of short deletions (S; 100 to 200 nt) or long deletions (L; around 2,000 nts).
Asterisks denote spliced mRNAs from segments M and NS that contaminated the virion preparation.
TABLE 4 Accumulation of abundant deletion-containing RNAs in wt
and mutant viruses
Virus
No. of abundant deletion-containing RNAs in segmenta
PB2 PB1 PA HA NP NA M NS
L S L S L S L S L S L S L S L S
Wt
2 20*
14 113
17 456
18 756 59 248 756
20 2,096 728 2,632 3,294
21 632 472 1,005
a The number of individual deletion-containing RNAs showing deletions longer than
15 nt that appear at least 20 times in each sample is given. Data were standardized
according to the number of deep-sequencing reads obtained for each virus sample and
are presented as numbers of short deletions (S; 100 to 200 nt) or long deletions (L;
around 2,000 nt). The asterisk denotes a spliced mRNA from segment NS that
contaminated the virion preparation.
FIG 9 Experimental verification of the presence of deleted genomic RNAs.
RNA samples from purified wt or mutant 2, 14, 17, 18, 20, and 21 virions were
used for RT-PCRusing terminal oligonucleotide primers corresponding to the
PB1, PB2, and PA RNA segments, and the PCR products were analyzed by
agarose gel electrophoresis. For mutants 18, 20, and 21, individual plaques
were isolated (plaques 18.3, 20.1, and 21.7), amplified, and used for RT-PCR
and agarose gel electrophoresis as described above.
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viruses were unable to block IFN-induced ISG expression, and the
mechanism underlying this defect is still unclear, but it may be a
result of DI RNA-mediated interference with nondefective virus
replication. Surprisingly, viral clones 18, 20, and 21 showed mu-
tations not in the polymerase genes but in the M1/M2 proteins,
and the relevance of mutations M1-I115M and M1-D30N was
verified by the phenotype of the corresponding recombinant vi-
ruses (Fig. 7). One possible explanation is that these mutants are
particularly prone to the encapsidation of deletion-containing
RNAs into the progeny virions (11, 87). Surprisingly, this does not
lead to low virus titers (Fig. 3 and data not shown), suggesting that
deletion-containing RNAs are incorporated in addition to nor-
mal-segment RNAs. As RIG-I has been shown to preferentially
associate with short influenza virus RNAs, including DI RNAs
FIG 10 Mapping themutations observed in selected virus populations andmutants. The diagram shows the location of mutations detected in virus populations
and individual virus mutants derived by serial passage in non-IFN-responsive cells and sorting for IFN-dependent GFP expression. The bars show each
virus-specific protein, and the numbers on the right denote the number of amino acids. Specific features of each protein are indicated. Arrowheads show the
position ofmutations observed inVS virus populations (black) or individual virusmutants (red). Filled arrowheads denote nonsynonymousmutations, whereas
empty arrowheads indicate synonymous mutations. The arrowhead size indicates the phylogenetic conservation of the mutation site.
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from the polymerase segments (70), the properties of 18/20/21
viruses would suggest that they are particularly good inducers of
the IFN response due to increased accumulation of deletion-con-
taining RNAs, rather than poor blockers of IFN induction (since
they possess intact NS1 proteins), in line with the recent report
showing the importance of DI RNAs in the innate response in vivo
(88). This phenotype, togetherwith the surprisingly high fitness of
these viruses, suggests their potential use as attenuated strains.
In summary, by serial passage of influenza viruses in non-
IFN-responsive cells, we have obtained virus populations and
individual virus clones that replicate better in these cells than in
IFN-responsive cells and are better able to induce IFN and
IFN-inducible genes than wt virus. The landscape of mutations
identified indicates that most of the mutant viruses express a wt
NS1 protein and that the mutations are widely distributed
among all viral genes. This suggests that essentially the entire
virus gene complement is tuned to counteract the IFN response
and that it drifts away from such an optimal sequence when the
IFN response is ablated.
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